Evidence map›Paper›PMID 41701408›Full record

ArticleEJNMMI radiopharmacy and chemistry2026

Exploring the theranostic potential of two metabolically stable GRPR-targeting peptides labelled with Ga-68 for PET imaging.

Karim Obeid, Ekaterina Bezverkhniaia, Vladimir Tolmachev, Anna Orlova, Panagiotis Kanellopoulos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Karim ObeidDepartment of Medicinal Chemistry, Uppsala University, 751 83, Uppsala, Sweden.
Ekaterina BezverkhniaiaDepartment of Medicinal Chemistry, Uppsala University, 751 83, Uppsala, Sweden.
Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 83, Uppsala, Sweden.
Anna OrlovaDepartment of Medicinal Chemistry, Uppsala University, 751 83, Uppsala, Sweden.
Panagiotis KanellopoulosDepartment of Medicinal Chemistry, Uppsala University, 751 83, Uppsala, Sweden. panagiotis.kanellopoulos@ilk.uu.se.ORCID http://orcid.org/0000-0002-0617-3936

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastrin-releasing peptide receptor (GRPR) attracts increasing attention as a target for radiotheranostic applications. We previously developed a metabolically stable GRPR-targeting peptide, incorporating α-methyl-L-tryptophan within its sequence (PEG

resultsIn this study, we aimed to evaluate the diagnostic counterparts of PKB2 and PKB3 by radiolabelling them with Ga-68 for positron emission tomography (PET) imaging. [

conclusions[

Indexed as

68GaBombesinGRPRImagingPETProstate cancerRadiopharmaceuticals

Identifiers

PMID41701408
PMCPMC12929764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.